Amarin (AMRN -7.8%) comes under pressure after the FDA's update to its Orange Book gives it's fish oil pill Vascepa "no unexpired exclusivity," though no NCE decision was made. [View news story]
Can't we all agree that the true determinant for the stock is the sales figures for Vascepa. If big pharma hasn't bought AMRN yet, I think they have moved on from NCE status. Companies just want to see how well the product sells.
Herbalife (HLF -11.9%) CEO Michael Johnson responds to Bill Ackman's accusation that the company is a 'pyramid scheme' countering that Ackman is improperly trying to manipulate Herbalife's stock and the SEC should take action. Johnson says company is a legitimate business with "millions of customers" and real business model. Ackman's short is about his own business model, not about HLF's. (video) [View news story]
Not questioning you, just curious. What other cases have you noticed?
Electric vehicle roundup: 1) Audi (VLKAY.PK) halts plans to develop the R8 e-tron due to high costs. 2) Legal experts see dealer groups only having a slim chance to convince state judges to grant injunctions that will stop Tesla (TSLA +0.3%) from operating retail stores. 3) The Chevrolet Volt gets some publicity when President Obama reveals he took one for a spin on the grounds of the White House. 4) Toyota will introduce new hybrid Lexus models in the U.S. after 2012 YTD hybrid sales beat expectations. [View news story]
Have there been any announcements from Toyota regarding new Lexus hybrid models? Will they be adding hybrid options to the models that they already offer or are they only adding different styles to the current hybrid models?
Amarin (AMRN +1.6%) bucks a weak tape this morning after saying that the USPTO has issued two patents covering the use of it's VascepaTM capsules for treating Hypertriglyceridemia. The patent issuance is part of AMRN's effort to protect the commercial potential of the drug through 2030, and it plans to list both patents in the FDA's Orange Book. [View news story]
Amarin (AMRN -7.8%) comes under pressure after the FDA's update to its Orange Book gives it's fish oil pill Vascepa "no unexpired exclusivity," though no NCE decision was made. [View news story]
Herbalife (HLF -11.9%) CEO Michael Johnson responds to Bill Ackman's accusation that the company is a 'pyramid scheme' countering that Ackman is improperly trying to manipulate Herbalife's stock and the SEC should take action. Johnson says company is a legitimate business with "millions of customers" and real business model. Ackman's short is about his own business model, not about HLF's. (video) [View news story]
Herbalife (HLF): Q3 EPS of $1.04 beats by $0.03. Revenue of $1.02B (+14% Y/Y) beats by $60M. (PR) [View news story]
Electric vehicle roundup: 1) Audi (VLKAY.PK) halts plans to develop the R8 e-tron due to high costs. 2) Legal experts see dealer groups only having a slim chance to convince state judges to grant injunctions that will stop Tesla (TSLA +0.3%) from operating retail stores. 3) The Chevrolet Volt gets some publicity when President Obama reveals he took one for a spin on the grounds of the White House. 4) Toyota will introduce new hybrid Lexus models in the U.S. after 2012 YTD hybrid sales beat expectations. [View news story]
Amarin (AMRN +1.6%) bucks a weak tape this morning after saying that the USPTO has issued two patents covering the use of it's VascepaTM capsules for treating Hypertriglyceridemia. The patent issuance is part of AMRN's effort to protect the commercial potential of the drug through 2030, and it plans to list both patents in the FDA's Orange Book. [View news story]